Please assess the completion status of the following clinical trial:

Trial Title: Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 85 years~* A body weight of greater than 50 Kg~* A requirement that no more than 15 days had passed between symptomatic presentation, confirmation of RVO and entry into the study.~Exclusion Criteria:~* Modification of the optic media transparency that could compromise the evaluation of fluorescein angiography, such as cataract or corneal degeneration~* History of major ocular surgery (with the exclusion of cataract extraction)~* Previous RVO~* Other ocular conditions that, in the opinion of the investigator, could have affected macular edema or altered visual acuity during the course of the study - Contraindications to the study drugs (e.g. major bleeding or neurosurgical procedures in the previous 3 months, serum creatinine levels of greater than 2.0 mg/dL, severe liver insufficiency, platelet count \< 100,000 mm3, known active peptic gastric ulcer)~* Active malignancy~* Pregnancy~* Inability to attend for follow up or anticipated non-compliance~* Ongoing treatment with aspirin or anticoagulant drugs at the time of RVO diagnosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): parnaparin, low molecular weight heparin
- 2 (Type: ACTIVE_COMPARATOR): aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).